Correlation between HIV viral load, increased fibrogenesis and HCV genotypes among HIV positive patients in Georgia

Abstract number: P1201

Karchava M., Sharvadze L., Dolmazashvili E., Abutidze A., Gatserelia L., Dvali N., Dzigua L., Tsertsvadze T.

Background: The progression of hepatitis C virus (HCV)-related liver disease is accelerated in patients infected with HIV. The aim of this study was to evaluate risk factors for the development of fibrosis in co-infected patients at baseline visit.

Methods: In a prospective analysis of 249 HCV co-infected patients, associations between liver fibrosis score, and liver enzime levels, HCV viral loads, HIV viral loads, HCV genotypes, CD4 counts were assessed. All analises were done on patients at baseine visit before ART initiation. Measurement of HIV and HCV RNA viral load was done by COBAS TaqMan 48 analiser. HCV genotyping was done by reverse hybridization line probe assay using VERSANT HCV Genotype kit 2.0 respectively. Transient elastography was performed by Fibroscan (Echosens, Paris, France). The median value of 10 successful acquisitions, expressed in kilopascal (kpa) with a success rate of at least 60% is used for liver stiffness measurement for BMI < 28 and 35% for the liver stiffness measurement in case of BMI > 28. LS < 5.5 kPa was considered as fibrosis stage F0-F1 by Metavir, 5.5–8.0 kPa – fibrosis stage F2, 8.0–10.0 kPa – fibrosis stage F2–F3, 10.0–12.5 kPa – fibrosis stage F3, 12.5–14 kPa – fibrosis stage F3–F4 and LS > 14.0 kPa – fibrosis stage F4 by Metavir.

Results: Statistical analysis demonstrated a significant correlation between both ALT and AST levels and HIV viral loads with at least mild fibrosis. Higher number of HIV viral load, length of HIV infection was assosiated with the high number of LS. Study revealed no correlations between CD4 cell counts, HCV viral loads or different HCV genotypes with fibrosis.

Conclusion: Our study revealed coreletion of HIV viral loads ALT and AST levels with liver fibrosis. These findings suggest a direct role for HIV in development of liver fibrosis as well as high liver enzime levels in HCV co-infected individual. This findings support the need to maintain low HIV viral loads and along the need for initation of HCV treatment in order to minimize HCV disease progression among HIV infected patients.

Session Details

Date: 10/04/2010
Time: 00:00-00:00
Session name: Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases
Location: Vienna, Austria, 10 - 13 April 2010
Presentation type:
Back to top